MyoKardia Announces Abstracts Selected for Presentation at the American Heart Association Scientific Sessions 2019
Among the highlights of
In lieu of a third quarter financial results conference call,
A complete list of the planned MyoKardia and SHaRe research presentations is detailed below:
Session: Heart Failure: Risk Prediction
1:30 p.m – 2:00 p.m ET
ORAL PRESENTATION: Sa2077: Female Sex, Multiple Sarcomere Variants and Atrial Fibrillation Are Associated With Worse Outcome in Patients With End-Stage Hypertrophic Cardiomyopathy
Lead author:
Session: On the Road to Translation: Moving Beyond Rodents
MODERATED POSTER: MDP156: Chronic Treatment With a Mavacamten-Like Myosin-Modulator (MYK-581) Blunts Disease Progression in a Mini-Pig Genetic Model of Non-Obstructed Hypertrophic Cardiomyopathy: In Vivo Evidence for Improved Relaxation and Functional Reserve
Lead author:
Session: Drug Discovery and Targets in LV Dysfunction
POSTER: Su1154: Pro-Compliant Effects of Mavacamten Are Preserved in the Setting of β-adrenergic Receptor Blockade: In vivo and ex vivo Evidence
Lead author:
Session: Top Rated Abstracts in Heart Failure: Predictors and Biomarkers
10:30 a.m – 10:35 a.m ET
POSTER: RF285: Predictors of End-Stage Hypertrophic Cardiomyopathy
Lead author:
Session: Cardiomyopathy: Hypertrophic and Amyloid
POSTER: Mo2319: Temporal Trend in Age at Diagnosis of Hypertrophic Cardiomyopathy: An Analysis of the SHaRe Registry
Lead author:
Session: Pharmacological Therapy in HF/Cardiomyopathy: The Next Important Indication or Agent?
ORAL PRESENTATION: RF295: Precision Pharmacological Treatment for Obstructive Hypertrophic Cardiomyopathy With Mavacamten: One-Year Results From PIONEER-OLE
Lead author:
Session: Pharmacological Therapy in HF/Cardiomyopathy: The Next Important Indication or Agent?
ORAL PRESENTATION: RF296: MYK-491, a Novel Small-Molecule Cardiac Myosin Activator Increases Cardiac Systolic Function and Preserves Mechanical Efficiency: Pre-Clinical in vivo and in vitro Evidence
Lead author:
Conference Call and Webcast
About
MyoKardia’s mission is to change the world for people with serious cardiovascular disease through bold and innovative science.
ContactsMichelle Corral Senior Director, Corporate Communications and Investor RelationsMyoKardia, Inc. 650-351-4690 ir@myokardia.comHannah Deresiewicz (investors) Stern Investor Relations, Inc. 212-362-1200 hannah.deresiewicz@sternir.comJulie Normant (Media) W2O 628-213-3754 jnormart@w2ogroup.com
Source: MyoKardia, Inc.